Kanser Tanısı ve Moleküler Biyobelirteçler

1.Sarhadi VK, Armengol G. Molecular biomarkers in cancer. Biomolecules. 2022;12(8):1021. doi:10.3390/biom12081021

2.Liu H, Karsidag I, Golin R, et al. Bridging discovery and treatment: Cancer biomarker. Cancers. 2025;17(22):3720. doi:10.3390/cancers17223720

3.Tuncer Z. Biomarkers. Gevher Nesibe Journal of Medical and Health Sciences. 2023;8(2):366–370. doi:10.5281/zenodo.7926896

4.Uygur MM, Gümüş M. The utility of serum tumor markers CEA and CA 15-3 for breast cancer prognosis and their association with clinicopathological parameters. Cancer Treatment and Research Communications. 2021;28:100402. doi:10.1016/j.ctarc.2021.100402

5.Huang G, Chen R, Lu N, et al. Combined evaluation of preoperative serum CEA and CA125 as an independent prognostic biomarker in patients with early-stage cervical adenocarcinoma. OncoTargets and Therapy. 2020;13:5155–5164. doi:10.2147/OTT.S250614

6.Strum S, Vincent M, Gipson M, et al. Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management. Oncotarget. 2024;15:381–388. doi:10.18632/oncotarget.28566

7.Rostami S, Stutterheim HW, Maxouri O, et al. Imaging of cancer of unknown primary: A systematic literature review of the past, present, and future. British Journal of Radiology. 2025;98(1172):1209–1226. doi:10.1093/bjr/tqaf039

8.Pulumati A, Dwarakanath BS, Verma A, et al. Technological advancements in cancer diagnostics: Improvements and limitations. Cancer Reports. 2023;6(2):e1764. doi:10.1002/cnr2.1764

9.Mohammadzadeh S, Mohebbi A, Moradi Z, et al. Comparing diagnostic performance of PET/CT, MRI, and CT in characterization of cN0 head and neck squamous cell carcinoma. Radiography. 2025;31(2):102902. doi:10.1016/j.radi.2025.102902

10.Engbersen MP, Van Driel W, Lambregts D, Lahaye M. The role of CT, PET-CT, and MRI in ovarian cancer. British Journal of Radiology. 2021;94(1125):20210117. doi:10.1259/bjr.20210117

11.Tetikoğlu E, Bilgili Tetikoğlu E. Yeni nesil dizileme teknolojilerinin kanser tanısındaki yeri. Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi. 2025;39(1):1–10.

12.Parums DV. Tumour biomarkers and personalised cancer therapy. Medical Science Monitor. 2023;29:e939420. doi:10.12659/MSM.939420

13.Bayram F, Ergül N. Kanser tanı ve takibinde kullanılan moleküler patoloji yöntemleri. Türkiye Klinikleri Tıbbi Genetik Dergisi. 2021;6(2):85–95.

14.Aydın Meriçöz Ç, Güler G, Önder S. The comparison of real-time PCR and mutation-specific immunohistochemistry in EGFR mutation analysis of non-small cell lung carcinomas. Hitit Medical Journal. 2024;6(2):117–125. doi:10.52827/hititmedj.1351295

15.Isaic A, Parums DV. Next-generation sequencing in oncology: Clinical applications and future perspectives. Medical Science Monitor. 2025;31:e941230. doi:10.12659/MSM.941230

16.Ma X, Zhu L, Wu X, et al. Liquid biopsy in cancer diagnosis and prognosis: Current status and future perspectives. Signal Transduction and Targeted Therapy. 2024;9(1):42. doi:10.1038/s41392-024-02021-w

17.Ho JWK, Choi J, Wong SQ. Clinical applications of circulating tumor DNA in solid cancers. Nature Reviews Clinical Oncology. 2024;21(2):85–102. doi:10.1038/s41571-023-00798-4

18.Tetikoğlu E, Bilgili Tetikoğlu E. Kanserde moleküler tanı yöntemleri ve klinik uygulamalar. Hitit Tıp Dergisi. 2021;3(2):95–104.

19.Henry NL, Hayes DF. Cancer biomarkers. Molecular Oncology. 2016;10(5):593–602. doi:10.1016/j.molonc.2016.01.010

20.Hotz C, Hutchinson L, Boddington S, et al. Genomic biomarkers in cancer immunotherapy. Nature Reviews Cancer. 2022;22(11):659–676. doi:10.1038/s41568-022-00483-8

21.Passaro A, Mok T, Peters S, et al. Recent advances on tumor mutational burden and actionable genomic alterations in lung cancer. Annals of Oncology. 2024;35(1):12–25. doi:10.1016/j.annonc.2023.10.007

22.Malik D, He Y, Kandeel F. Molecular imaging biomarkers for early cancer detection. Cancers. 2024;16(3):512. doi:10.3390/cancers16030512

23.Sha D, Jin Z, Budczies J, et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discovery. 2020;10(12):1808–1825. doi:10.1158/2159-8290.CD-20-0522

24.Dienstmann R, Vermeulen L, Guinney J, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nature Reviews Cancer. 2017;17(2):79–92. doi:10.1038/nrc.2016.126

25.Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2016;406(6797):747–752. doi:10.1038/35021093

26.Wang Z, Gerstein M, Snyder M. RNA-Seq: A revolutionary tool for transcriptomics. Nature Reviews Genetics. 2016;10(1):57–63. doi:10.1038/nrg2484

27.Esteller M. Non-coding RNAs in human disease. Nature Reviews Genetics. 2018;12(12):861–874. doi:10.1038/nrg3074

28.Kristensen LS, Andersen MS, Stagsted LVW, et al. The biogenesis, biology and characterization of circular RNAs. Nature Reviews Genetics. 2019;20(11):675–691. doi:10.1038/s41576-019-0158-7

29.Diamandis EP. Cancer biomarkers: Can we turn recent failures into success? Journal of the National Cancer Institute. 2017;109(8):djx097. doi:10.1093/jnci/djx097

30.Duffy MJ, Crown J, O’Donovan N. Biomarkers in breast cancer: Where are we and where are we going? Advances in Clinical Chemistry. 2020;95:1–23. doi:10.1016/bs.acc.2019.10.001

31.Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harbor Perspectives in Biology. 2016;8(9):a019505. doi:10.1101/cshperspect.a019505

32.Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metabolism. 2016;23(1):27–47. doi:10.1016/j.cmet.2015.12.006

33.Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168(4):657–669. doi:10.1016/j.cell.2016.12.039

34.Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646–674.

35.Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine. 2014;6(224):224ra24. doi:10.1126/scitranslmed.3007094

36.Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nature Reviews Cancer. 2017;17(4):223–238. doi:10.1038/nrc.2017.7

37.Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926–930. doi:10.1126/science.aar3247

38.Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncology. 2019;5(12):1710–1717. doi:10.1001/jamaoncol.2019.3616

39.Li J, Liu L, Feng Z, et al. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: A cohort study. Breast Cancer. 2020;27(4):621–630. doi:10.1007/s12282-020-01058-3

40.Geiger K, Joerger M, Roessler M, et al. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients. Tumour Biology. 2024;46(Suppl 1):S191–S206. doi:10.3233/TUB-230014

41.Hing JX, Mok CW, Tan PT, et al. Clinical utility of tumour marker velocity of CA 15-3 and CEA in breast cancer surveillance. Breast. 2020;52:95–101. doi:10.1016/j.breast.2020.05.005

Huang G, Chen R, Lu N, et al. Combined evaluation of preoperative serum CEA and CA125 as an independent prognostic biomarker in patients with early-stage cervical adenocarcinoma. OncoTargets and Therapy. 2020;13:5155–5164. doi:10.2147/OTT.S250614

Xiang J, Peng J, Xing Z, et al. Potential supplementary tumor markers for liquid biopsy in non-small cell lung cancer. Experimental Biology and Medicine. 2025;250:10523. doi:10.3389/ebm.2025.10523

Strum S, Vincent M, Gipson M, et al. Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management. Oncotarget. 2024;15:381–388. doi:10.18632/oncotarget.28566

Zhang Z, Yuan F, Chen R, et al. Dynamics of serum tumor markers can serve as a prognostic biomarker for Chinese advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors. Frontiers in Immunology. 2020;11:1173. doi:10.3389/fimmu.2020.01173

Li S, Zeng Z, Hong Z, et al. The heterogeneous expression patterns of serum tumor markers in non-small cell lung cancer patients are predictive factors for progression-free survival. Discover Oncology. 2025;16(1):1121. doi:10.1007/s12672-025-02969-3

Üçüncü MZ. Kolorektal kanserlerin tanı ve prognostik takibinde eski ve yeni serum biyobelirteçleri: Sistematik inceleme ve meta-analiz. IGUSABDER. 2019;902–919.

O S. Genel cerrahi kliniğinde yatan hastalarda AFP, CEA, CA19-9, CA125 ve PSA düzeylerinin analizi. Konuralp Medical Journal. 2013;5(3):13–17.